Spirulina
Spirulina: What 156 human studies show, including 76 randomized controlled trials – organized by area of application and strength of evidence.
We evaluated 156 human studies on Spirulina, including 76 randomised controlled trials and 29 meta-analyses or systematic reviews; the controlled studies include 6,760 participants in total. As of 8 October 2026.
1. What Is Spirulina? Occurrence, Origin and Forms
Spirulina is the dried biomass of filamentous cyanobacteria of the genus Arthrospira, mainly Arthrospira platensis and Arthrospira maxima. It grows naturally in alkaline soda lakes and is today cultivated in open ponds and closed systems. Traditionally it is eaten as dried cakes; today it serves mainly as a dietary supplement and as a protein-rich food ingredient.
Natural occurrences are in alkaline, mineral-rich soda lakes in Africa, Asia and Central America; for commercial use it is grown in culture ponds or photobioreactors. It is used as a powder, tablet or food additive, and in studies mainly as the dried whole biomass.
Spirulina is obtained by cultivation in alkaline nutrient solutions, harvesting of the filaments and gentle drying into a dark green powder that is further processed into tablets or capsules. Studies examine mainly the dried whole biomass in powder, tablet or capsule form, as well as foods and beverages fortified with spirulina.
Forms and Preparations Studied
- Dried powder of the whole biomass
- Tablets and capsules
- Foods and beverages fortified with spirulina
- Fresh or frozen biomass
- Arthrospira platensis and Arthrospira maxima as different species
Not covered on this page:
- Chlorella and other green algae or microalgae such as Chlorella vulgaris
- Aphanizomenon flos-aquae and other wild-harvested cyanobacteria from lakes
- Phycocyanin isolated from spirulina as a single substance
- Products that mix several microalgae or additional active substances and are offered as blue-green algae
2. What Does Spirulina Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Body weight and body composition | mixed | high | 7 meta-analyses · 23 controlled · 8 other | 1,334 |
| Blood lipids | mixed | high | 8 meta-analyses · 15 controlled · 12 other | 1,014 |
| Blood glucose and metabolism | mostly improved | high | 6 meta-analyses · 13 controlled · 11 other | 664 |
| Oxidative stress and antioxidants | mostly improved | high | 2 meta-analyses · 15 controlled · 14 other | 729 |
| Physical performance | mixed | high | 1 meta-analyses · 12 controlled · 7 other | 235 |
| Blood pressure | mostly no difference | moderate | 8 meta-analyses · 9 controlled · 7 other | 408 |
| Allergic conditions (e.g., allergic rhinitis) | mostly improved | moderate | 2 meta-analyses · 1 controlled · 5 other | 0 |
| Other investigations | mostly improved | high | 6 meta-analyses · 62 controlled · 34 other | 5,684 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Spirulina, Body Weight and Body Composition: Human Studies
For body weight and body composition, meta-analyses are favorable, controlled individual studies mixed. Meta-analyses found lower body weight in adults 61819 and weight gain in malnourished children 4. Two randomized controlled trials found more weight loss with spirulina than with placebo, in multiple sclerosis 42 and with a low-calorie diet 62. A randomized crossover trial with Arthrospira maxima lowered body fat percentage even without training 103. Appetite decreased with spirulina compared with baseline 62; with strength training, hunger fell in all groups, most strongly with spirulina 54. Individual studies found no difference in weight 40, in anthropometric parameters 4668 or in body fat percentage 90. With mixtures containing chlorella and other algae 16, with structured training 13, with HIIT 69 or with turmeric 72, the effect cannot be attributed to spirulina alone. The robustness is high, but most studies are small and short.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Sukmawati et al. 2025 | meta-analysis · 1,335 participants | Spirulina supplementation; vs. Control without spirulina | Weight: improved (SMD = 0.33, 95 % CI [0.22, 0.45], p < 0.00001); Mid-upper arm circumference (MUAC): improved (SMD = 0.71, 95 % CI [0.31, 1.11], p = 0.0005); Height: no difference (SMD = -0.25, 95 % CI [-1.36, 0.85], p = 0.65) |
| 6 Fu et al. 2025 | meta-analysis · 1,035 participants | Spirulina supplementation, alone or with exercise; vs. Control without spirulina | Body weight: improved (g = -0.30, 95% CI: -0.53 to -0.08); Body composition: no difference |
| 12 Azizi et al. 2026 | systematic review | Combined formulations, some co-administered with protein or spirulina; vs. Various controls of the primary studies | Body composition: improved |
| 13 Yasul et al. 2026 | meta-analysis | Spirulina supplementation, species not stated; 1-6 g/day; 6-12 weeks; vs. Spirulina plus exercise vs. control or supplementation alone | BMI: improved (-1.34 kg/m2); body fat percentage: improved (-3.03%) |
| 14 Mishra et al. 2026 | systematic review | Spirulina supplementation; vs. Control without Spirulina | Weight change: no difference (-0.526 (95% CI, -1.289 to 0.236)) |
| 16 Kazeminejad et al. 2025 | meta-analysis | Algae supplements, including Spirulina and Chlorella; vs. Placebo or control group | Body mass index: improved (WMD, -0.27 kg/m2 (95% CI, -0.42 to -0.13)); Body weight: improved (WMD: -0.78 kg [-1.18 to -0.38]); Waist circumference: improved (WMD, -0.68 cm [-1.27 to -0.10]) |
| 17 Gorgi et al. 2025 | review | Spirulina (Arthrospira platensis); vs. Control in animal studies and the RCT | Body weight (animal models): improved (MD=8.61, 95% CI=2.98 to 14.25) |
| 18 Shiri et al. 2025 | meta-analysis | Spirulina supplementation; vs. Placebo or control | Body weight: improved (WMD: -1.78 kg; P = 0.003); Body mass index: improved (WMD: -0.58 kg/m²; P = 0.001) |
Further studies in this area: 19 22 27 37 40 42 46 49 50 54 59 62 64 66 68 69 70 74 75 77 79 80 84 90 103 110 125 140 146 150
Spirulina and Blood Lipids: Human Studies
Meta-analyses found lower total and LDL cholesterol and triglyceride levels 56182628, also in type 2 diabetes 26 and in people with overweight 6; a meta-analysis on spirulina together with structured training also reports more favorable LDL and triglyceride levels as well as higher HDL cholesterol, although the result cannot be attributed to spirulina alone 13. In type 2 diabetes, triglycerides fell more than with placebo, and total and LDL cholesterol decreased 57; in people with HIV, blood lipids improved compared with baseline 39. In men with overweight, these improvements appeared mainly together with training 6070. A spirulina sauce lowered triglycerides and LDL cholesterol in type 2 diabetes, but not HDL cholesterol 75. In children with nephrotic syndrome, blood lipids fell with and without spirulina, numerically more with spirulina 112. No difference in blood lipids was found by a meta-analysis 8 as well as randomized controlled trials in healthy people and in women with overweight doing interval training 8292. The optimal amount, the significance of the species Arthrospira platensis compared with Arthrospira maxima and the question of whether the findings can be confirmed in healthy people without lipid metabolism disorders remain open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Osadnik et al. 2022 | meta-analysis · 13,062 participants | Spirulina among other nutraceuticals (network meta-analysis); vs. Placebo/no intervention and other nutraceuticals | LDL cholesterol: improved (-1.21 [-46.8 mg/dL] to -0.17 [-6.6 mg/dL] mmol/l reduction); Total cholesterol: improved (-1.75 [-67.7 mg/dL] to -0.18 [7 mg/dL] mmol/l reduction) |
| 5 Rahnama et al. 2023 | meta-analysis · 1,076 participants | Spirulina supplementation (form not specified in abstract); not reported in abstract; not reported in abstract; vs. Control groups of included RCTs | LDL cholesterol: improved (SMD: -0.6, 95% CI: -0.9, -0.2, P<0.05); Total cholesterol: improved (SMD: -0.6, 95% CI: -0.9, -0.2, P<0.05); Triglycerides: improved (SMD: -0.6, 95% CI: -0.9, -0.2, P<0.05) |
| 6 Fu et al. 2025 | meta-analysis · 1,035 participants | Spirulina supplementation, alone or with exercise; vs. Control without spirulina | Total cholesterol: improved (g = -0.79, 95% CI: -1.18 to -0.41); Triglycerides: improved (g = -0.64, 95% CI: -1.00 to -0.28); LDL-C: improved (g = -0.71, 95% CI: -1.13 to -0.29) |
| 8 Pinto-Leite et al. 2025 | meta-analysis · 299 participants | Spirulina supplement (species/form not reported); vs. Control/placebo in included RCTs | Total cholesterol: no difference (-0.17, 95% CI: -0.39 to 0.06, p = 0.15) |
| 13 Yasul et al. 2026 | meta-analysis | Spirulina supplementation, species not stated; 1-6 g/day; 6-12 weeks; vs. Spirulina plus exercise vs. control or supplementation alone | LDL-C: improved (-12.68 mg/dL); triglycerides: improved (-9.81 mg/dL); HDL-C: improved (4.21 mg/dL) |
| 18 Shiri et al. 2025 | meta-analysis | Spirulina supplementation; vs. Placebo or control | Triglycerides: improved (WMD: -14.75 (mg/dl); P < 0.001); Total cholesterol: improved (WMD: -11.5 (mg/dl); P < 0.001); LDL-C: improved (WMD: -7.69 (mg/dl); P < 0.001) |
| 22 Firdaus et al. 2025 | systematic review | Spirulina supplementation (form not specified); 20 mg to 6 g; 17–360 days; vs. not reported (systematic review of clinical studies) | Dyslipidemia: improved |
| 26 Hatami et al. 2021 | meta-analysis | Spirulina supplementation (form not specified); vs. Control (placebo/no supplementation) | Triglyceride: improved (-30.99 mg/dl; 95% CI: -45.20, -16.77); Total cholesterol: improved (-18.47 mg/dl; 95% CI: -33.54, -3.39); LDL-C: improved (-20.04 mg/dl; 95% CI: -34.06, -6.02) |
Further studies in this area: 27 28 39 48 57 60 62 64 67 70 75 76 82 92 106 109 110 112 125 129 136 137 138 140 144 152 155
Spirulina, Blood Glucose and Metabolism: Human Studies
Meta-analyses found lower fasting glucose, also in type 2 diabetes 2628; randomized controlled studies confirmed this in type 2 diabetes, HIV infection and Alzheimer's dementia 385657. Insulin resistance and insulin levels also improved in a meta-analysis 18, a randomized controlled study 56 and a non-randomized study in obese men with and without interval training 110. Insulin sensitivity improved in several studies, including one with Arthrospira maxima and one with Arthrospira platensis compared with soy 566483. Sauces fortified with spirulina did not change fasting glucose, HbA1c and insulin in fatty liver and type 2 diabetes 6875. The robustness is high, since several meta-analyses and controlled studies are available, but many investigations are small, short and do not always distinguish between the Arthrospira species.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Fu et al. 2025 | meta-analysis · 1,035 participants | Spirulina supplementation, alone or with exercise; vs. Control without spirulina | Glycemic control: no difference |
| 13 Yasul et al. 2026 | meta-analysis | Spirulina supplementation, species not stated; 1-6 g/day; 6-12 weeks; vs. Spirulina plus exercise vs. control or supplementation alone | fasting glucose: improved (-14.47 mg/dL) |
| 18 Shiri et al. 2025 | meta-analysis | Spirulina supplementation; vs. Placebo or control | Fasting blood glucose: improved (WMD: -5.51 (mg/dl); P = 0.001); HOMA-IR: improved (WMD: -0.68; P < 0.001); Insulin: improved (WMD: -0.86 (ng/ml); P = 0.002) |
| 22 Firdaus et al. 2025 | systematic review | Spirulina supplementation (form not specified); 20 mg to 6 g; 17–360 days; vs. not reported (systematic review of clinical studies) | Hyperglycemia: improved |
| 26 Hatami et al. 2021 | meta-analysis | Spirulina supplementation (form not specified); vs. Control (placebo/no supplementation) | Fasting blood glucose: improved (-17.88 mg/dl; 95% CI: -26.99, -8.78); HbA1C: no difference; Post prandial blood sugar: no difference |
| 27 Bobescu et al. 2020 | systematic review | Spirulina as food supplement | Hyperglycemia: improved |
| 28 Huang et al. 2018 | meta-analysis | Spirulina dietary supplement (species not stated); 1 to 19 g/day; 2 to 48 weeks; vs. Control arm without spirulina | Fasting blood glucose: improved (WMD = -5.01 mg/dL; 95% CI: -9.78 to -0.24; P=0.04) |
| 38 Ngo-Matip et al. 2015 | randomised controlled · 169 participants | Spirulina platensis (S. platensis) as dietary supplement; 12 months; vs. Standard care plus balanced local diet without S. platensis | Fasting blood glucose: improved |
Further studies in this area: 56 57 59 64 68 69 75 82 83 97 99 110 117 125 127 136 137 139 140 144 151 152
Spirulina, Oxidative Stress and Antioxidants: Human Studies
Controlled trials found less lipid peroxidation, measured as malondialdehyde or TBARS 5568115; with local application in periodontal pockets in periodontitis, malondialdehyde fell only in saliva, not in blood 108. Total antioxidant capacity was also higher in several controlled trials 43495568. A meta-analysis confirmed lower malondialdehyde and a higher total antioxidant capacity 2. Inflammatory markers improved: a meta-analysis found lower levels of interleukin-6 and hs-CRP 18, randomized controlled trials in Alzheimer's dementia and overweight a lower hs-CRP 5662. Superoxide dismutase activity increased in older women with spirulina 48 and in COPD patients compared with baseline 109. In rugby players, F2α-isoprostanes increased after exhaustive exercise only with placebo; the study does not report a direct group comparison 95. In people with hypertension, glutathione peroxidase and oxidized glutathione increased with Arthrospira maxima powder compared with baseline 96. A randomized controlled trial with Arthrospira platensis salad dressing in hypertension, by contrast, found no difference in total antioxidant capacity and in hs-CRP 67. The evidence is overall high, but many studies include small groups and short durations, and the influence on clinical endpoints remains open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Mousavi et al. 2025 | meta-analysis · 5,385 participants | Spirulina supplement; vs. Control/placebo | Malondialdehyde: improved (SMD: −0.929); Total antioxidant capacity: improved (SMD: 1.086) |
| 17 Gorgi et al. 2025 | review | Spirulina (Arthrospira platensis); vs. Control in animal studies and the RCT | Oxidative stress (animal models): improved; Oxidative stress (RCT): improved |
| 18 Shiri et al. 2025 | meta-analysis | Spirulina supplementation; vs. Placebo or control | TNF-α: improved (WMD: -0.46 pg/ml; P = 0.01); IL-6: improved (WMD: -0.58 pg/ml; P < 0.001); hs-CRP: improved (WMD: -0.86 mg/L; P = 0.002) |
| 21 Lacurezeanu et al. 2025 | systematic review | Arthrospira platensis and Chlorella vulgaris; vs. conventional iron supplementation or control | SOD and GPx activity, lipid peroxidation: improved |
| 43 Moradi et al. 2024 | randomised controlled · 80 participants | Spirulina (SP), two 500 mg capsules per day; 1 g/day; 8 weeks; vs. Placebo (PL) | Serum total antioxidant capacity: improved (p ≤ 0.001) |
| 48 Park et al. 2008 | randomised controlled · 78 participants | Spirulina (species not stated); 8 g/day; 16 weeks; vs. placebo, randomized double-blind | total antioxidant status: improved (p < 0.05); superoxide dismutase activity in women: improved (p < 0.05) |
| 49 Winter et al. 2014 | randomised controlled · 73 participants | Arthrospira platensis (Spirulina) capsules; 5 g/day; three months; vs. placebo of equal protein and energy content | total antioxidant capacity of the serum (TAOS): improved (increase of 56 (1-98) µM for Asp was significantly different from the decrease observed in the placebo group (p < 0.001)) |
| 55 Nasab et al. 2025 | randomised controlled · 60 participants | Spirulina (Arthrospira) platensis, capsules of 500 mg each; 1 g/day (two capsules daily); 12 weeks; vs. placebo, randomized, double-blind, parallel | Plasma total antioxidant capacity (TAC): improved (145.27 ± 30.77 vs. -54.90 ± 45.72; p < 0.001); Malondialdehyde (MDA): improved (-11.61 ± 2.57 vs. -2.00 ± 2.24; p < 0.001) |
Further studies in this area: 56 62 64 67 68 75 76 95 96 108 109 115 117 136 137 139 140 143 146 149 151 152 155
Spirulina and Physical Performance: Human Studies
A randomized crossover study with Arthrospira maxima in overweight men found a higher maximum oxygen uptake, with and without a training programme 61103104; another during arm crank exercise found a higher oxygen uptake until exhaustion 98. Time to exhaustion was prolonged in this study 103104 and in a placebo-controlled crossover study with runners 115. In the study with Arthrospira maxima, lactate accumulation also began later 103104; two further studies found more haemoglobin than with placebo 9498. By contrast, a randomized controlled study in rugby players found only a small, not confirmed advantage in jumping and sprinting and no difference in strength 90. Spirulina Nigrita® did not change strength and muscle soreness after exercise 116. In cyclists, a randomized controlled study found no difference in maximum performance, heart rate, oxygen uptake and time to exhaustion 94. A systematic review on spirulina as Arthrospira platensis reports a better oxygen uptake and exercise tolerance at submaximal exercise, but no difference in physical performance in strength athletes 25. A meta-analysis on spirulina, chlorella, brown algae polysaccharides and astaxanthin found a longer time to exhaustion and a trend towards higher VO2max 7; another on spirulina with structured training found a higher VO2max 13. In these mixtures, the share of spirulina alone cannot be attributed 713.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 7 Wei et al. 2026 | meta-analysis · 822 participants | Algae supplements including Spirulina, Chlorella, brown-algal polysaccharides, astaxanthin; vs. Placebo or control in RCTs | VO2max: improved (SMD = 0.88, 95% CI: 0.00-1.75); Time to exhaustion: improved (SMD = 1.06, 95% CI: 0.16-1.96); Maximal power output: improved (SMD = 0.29, 95% CI: 0.03-0.55) |
| 12 Azizi et al. 2026 | systematic review | Combined formulations, some co-administered with protein or spirulina; vs. Various controls of the primary studies | Muscular strength: improved |
| 13 Yasul et al. 2026 | meta-analysis | Spirulina supplementation, species not stated; 1-6 g/day; 6-12 weeks; vs. Spirulina plus exercise vs. control or supplementation alone | VO2max: improved (3.25 mL/kg/min) |
| 25 Calella et al. 2022 | systematic review | Spirulina (Arthrospira platensis) | Oxygen uptake and exercise tolerance during submaximal exercise: improved; Physical performance in power athletes: no difference |
| 69 Delfan et al. 2024 | randomised controlled · 44 participants | spirulina supplement or placebo; 12 weeks; vs. control, spirulina alone, HIIT alone, spirulina+HIIT | VO2peak: improved (p < 0.05) |
| 74 Pour et al. 2026 | randomised controlled · 40 participants | Spirulina tablets, partly with probiotics; 2 g spirulina daily (2×1 g); 8 weeks; vs. Placebo, probiotics alone, spirulina alone | agility: no difference (P = 0.001); isokinetic average power knee extension 60°/s: no difference (P = 0.018); isokinetic average power knee extension 180°/s: no difference (P = 0.009) |
| 80 Akbarzadeh et al. 2025 | randomised controlled · 36 participants | Spirulina or placebo, twice daily; 500 mg each, twice daily; eight weeks; vs. placebo with aerobic exercise, spirulina with aerobic exercise, spirulina-only, placebo-only | VO2max: no difference (p < .001); VO2max between groups: no difference |
| 81 van et al. 2023 | randomised controlled · 36 participants | Spirulina (SPIR) drink containing 25 g protein; 25 g protein from Spirulina, single bolus; 4 h postprandial period; vs. Mycoprotein (MYCO) and chlorella (CHLO), 25 g protein each | Myofibrillar protein synthesis rate in rested muscle: no difference (from 0.042 ± 0.030 to 0.066 ± 0.022%·h-1); Myofibrillar protein synthesis rate in exercised muscle: no difference (from 0.038 ± 0.011 to 0.086 ± 0.028%·h-1); Myofibrillar protein synthesis rate between groups: no difference (P > 0.05) |
Further studies in this area: 90 91 94 98 103 105 115 116 138 143 146 153
Spirulina and Blood Pressure: Human Studies
Several meta-analyses found a lower diastolic blood pressure with spirulina, especially in high blood pressure and overweight 6810151828. Systolic blood pressure also fell in meta-analyses 101518; three small studies found a reduction only within the spirulina group, without a group comparison 677996. A systematic review reports an improvement in hypertension in metabolic syndrome 22; another considers an effect in postmenopausal women possible and calls for clinical trials on this 27. Endothelial function improved in overweight people with hypertension with Arthrospira maxima powder compared with baseline 79. These positive findings are contrasted by four randomized controlled trials in which blood pressure did not differ 46506882: one investigated Arthrospira platensis capsules in ulcerative colitis 46, one softgel capsules in depression 50, one a sauce fortified with Arthrospira platensis in non-alcoholic fatty liver disease 68 and one spirulina powder in healthy adults without hypercholesterolemia 82. A yogurt-like dessert fortified with Arthrospira platensis did not lower blood pressure in people with overweight and did not improve vascular values 52. The evidence is moderate: the meta-analyses are favorable, the controlled individual studies mostly without a confirmed difference; which amount and preparation works remains open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Fu et al. 2025 | meta-analysis · 1,035 participants | Spirulina supplementation, alone or with exercise; vs. Control without spirulina | Diastolic blood pressure: improved (g = -0.73, 95% CI: -1.43 to -0.03) |
| 8 Pinto-Leite et al. 2025 | meta-analysis · 299 participants | Spirulina supplement (species/form not reported); vs. Control/placebo in included RCTs | Diastolic blood pressure: improved (-0.42, 95% CI: -0.81 to -0.02, p = 0.04) |
| 10 Machowiec et al. 2021 | meta-analysis · 230 participants | Spirulina supplement (species/form not stated); 1 to 8 g per day; 2 to 12 weeks; vs. Control (placebo/no supplementation) | Systolic blood pressure: improved (MD: -4.59 mmHg, 95% CI: -8.20 to -0.99); Diastolic blood pressure: improved (MD: -7.02 mmHg, CI: -8.86 to -5.18) |
| 15 Shiri et al. 2025 | meta-analysis | Spirulina (form not stated in abstract); not reported in abstract; subgroup analysis for more than 8 weeks intervention; vs. control or placebo group | Systolic blood pressure: improved (WMD: -4.41 mmHg, 95% CI: -6.74 to -2.07); Diastolic blood pressure: improved (WMD: -2.84 mmHg, 95% CI: -4.65 to -1.03) |
| 18 Shiri et al. 2025 | meta-analysis | Spirulina supplementation; vs. Placebo or control | Systolic blood pressure: improved (WMD: -3.85 mmHg, P = 0.002); Diastolic blood pressure: improved (WMD: -3.09 mmHg, P < 0.001) |
| 22 Firdaus et al. 2025 | systematic review | Spirulina supplementation (form not specified); 20 mg to 6 g; 17–360 days; vs. not reported (systematic review of clinical studies) | Hypertension: improved |
| 27 Bobescu et al. 2020 | systematic review | Spirulina as food supplement | Blood pressure: improved |
| 28 Huang et al. 2018 | meta-analysis | Spirulina dietary supplement (species not stated); 1 to 19 g/day; 2 to 48 weeks; vs. Control arm without spirulina | Diastolic blood pressure: improved (WMD = -7.17 mmHg; 95% CI: -8.57 to -5.78; P=0.001) |
Further studies in this area: 46 50 52 67 68 79 82 96 97 125 137 138 139 140 144 152
Spirulina and Allergic Conditions (e.g., Allergic Rhinitis): Human Studies
A systematic review found less runny nose, blocked nose and itching in allergic rhinitis; the authors rate the evidence as very low because of only two studies 11. The robustness is moderate: the findings are based mainly on review articles; larger randomized studies stating species, form and amount are still pending.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 11 Batista et al. 2021 | systematic review · 215 participants | Spirulina as dietary supplement (form not reported); vs. Control group in the included studies | Runny nose, nasal congestion and itching over time of medication use: improved (p<0.001); Prevalence of rhinorrhea: improved (P = 0.021); Nasal congestion or obstruction: improved (P = 0.039) |
| 29 Laccourreye et al. 2017 | systematic review | Extracts of various herbs, including spirulina; vs. Placebo | Superiority in allergic rhinitis: improved |
| 30 Karkos et al. 2007 | systematic review | Spirulina (species not stated); 12 weeks; vs. Placebo in the RCT | effect in allergic rhinitis: improved |
| 118 Cingi et al. 2008 | controlled | Spirulina as dietary supplement; vs. Placebo | Symptoms and physical findings of allergic rhinitis: improved (P < 0.001***) |
| 122 Sayin et al. 2013 | cross-sectional study · 230 participants | Herbal supplements, including Spirulina | Proportion of patients using Spirulina (5.7%) |
| 133 Gromek et al. 2024 | review · 5 participants | Spirulina (Arthrospira), mainly as dietary supplement; vs. no control group, review | Allergic reactions per WAO Anaphylaxis Guidance 2020: worsened (four of five); Antiallergic properties of spirulina: improved |
| 135 Srisuwatchari et al. 2026 | review | Spirulina as a whole-food supplement | Immediate hypersensitivity reactions (incl. anaphylaxis): worsened |
| 154 Karkos et al. 2011 | review | Spirulina (Arthrospira), blue-green alga | Antiallergic effect: unclear |
Spirulina: Further Outcomes in Studies
Investigated were predominantly Arthrospira platensis, in the form of powder, capsules and tablets as well as fortified foods; mixtures with other microalgae or additives cannot be attributed to spirulina alone. The transferability to other spirulina species and forms as well as long-term effects remain open, since many studies were small and of short duration.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Mousavi et al. 2025 | meta-analysis · 5,385 participants | Spirulina supplement; vs. Control/placebo | CRP: improved (SMD: −0.972 mg/dl); Interleukin-6: improved (SMD: −0.532); TNF-α: improved (SMD: −0.579 mg/dl) |
| 3 Bayo et al. 2025 | systematic review · 3,582 participants | Spirulina among numerous other natural compounds, no details on species or form; 8 weeks to 2 years, mean 12.5 months; vs. no uniform comparator, designs highly variable | Cognitive and neuroprotective benefit: unclear |
| 9 Shahraki et al. 2025 | meta-analysis · 283 participants | Spirulina supplement; not reported in abstract; not reported in abstract; vs. control group | serum CRP: improved (WMD: -0.55 mg/L; 95% CI: -0.90 to -0.21; p = 0.002) |
| 13 Yasul et al. 2026 | meta-analysis | Spirulina supplementation, species not stated; 1-6 g/day; 6-12 weeks; vs. Spirulina plus exercise vs. control or supplementation alone | inflammatory markers and adipokines (CRP, TNF-α, MCP-1, IL-6, IL-8): unclear |
| 17 Gorgi et al. 2025 | review | Spirulina (Arthrospira platensis); vs. Control in animal studies and the RCT | Clinical features (animal models): improved (SMD=-2.39, 95% CI=-2.95 to -1.83); Colon length (animal models): improved (MD=1.25, 95% CI=0.59 to 1.91); Inflammatory markers (animal models): improved |
| 20 Shu et al. 2025 | systematic review | Spirulina as dietary supplement | Fatigue, injury recovery, immune function: unclear (current evidence remains insufficient) |
| 21 Lacurezeanu et al. 2025 | systematic review | Arthrospira platensis and Chlorella vulgaris; vs. conventional iron supplementation or control | hemoglobin, serum ferritin and red blood cell counts: improved; inflammation-induced hepcidin levels: improved |
| 23 Fu et al. 2023 | systematic review | Spirulina as nutritional intervention, form not specified; vs. other nutritional interventions or control, not specified | Alleviation of tuberculosis-drug-induced liver injury: improved (moderate evidence) |
Further studies in this area: 24 25 29 30 31 32 33 34 35 36 37 38 40 41 42 43 44 45 46 47 48 49 50 51 53 55 56 58 59 63 65 68 69 70 71 73 75 77 78 80 81 84 85 86 87 88 89 91 92 93 94 95 99 100 101 102 105 106 107 108 111 113 114 115 116 119 120 121 123 124 126 128 129 130 131 132 134 136 137 138 139 140 141 142 143 145 146 147 148 149 150 152 154 155
4. How Is Spirulina Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used dried powder of the whole biomass, tablets, capsules as well as foods and drinks enriched with spirulina. Mainly Arthrospira platensis and Arthrospira maxima were studied; the table shows the amounts tested. Individual studies tested mixtures, for example with chlorella, other algae, turmeric or together with training, so the contribution of spirulina cannot be attributed on its own there.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Spirulina (species not stated) | 1 g twice daily | 14 days | 31 |
| Maize-soy porridge with Spirulina platensis (SP) vs. without (CON) | — | 16 months supplementation, follow-up in 2018 | 32 |
| Spirulina platensis added to soya-maize porridge | — | 12 months | 33 |
| Spirulina corn soy blend (SCSB) porridge | 200 ml porridge three times daily, 1.7 kg flour per child | 6 months | 34 |
| PMSoff, a multi-ingredient supplement containing spirulina | — | two months | 35 |
| Spirulina (Arthrospira platensis) supplement plus standard treatment | 15.2 g Spirulina per day | 6 days, follow-up to day 7 | 36 |
| Spirulina powder versus placebo | 2 g per day, 100 g in total | Two phases with 5-week wash-out in between | 37 |
| Spirulina platensis (S. platensis) as dietary supplement | — | 12 months | 38 |
| Spirulina platensis (Cyanobacteriaceae) supplementation | — | three, six and twelve months | 39 |
| Spirulina supplement (species not stated) | 10 g spirulina per day | 6 months | 40 |
| Spirulina platensis (Sp) | 5 g daily | 2 weeks | 41 |
| Spirulina (Arthrospira) platensis | 1 g/day | 12 weeks | 42 |
| Spirulina (SP), two 500 mg capsules per day | 1 g/day | 8 weeks | 43 |
| Spirulina, two 500 mg capsules daily | 1 g/day | 8 weeks | 44 |
| Spirulina maxima 70% ethanol extract (SM70EE) | 1 g/day | 12 weeks | 45 |
5. Is Spirulina Safe? Side Effects in Studies
Tolerability is predominantly described as good in the studies; in some cases no side effects were observed 36. Individual studies reported a slight increase in creatinine 4049; a skin gel with spirulina extract caused only very few local side effects 113. Review articles describe rare hypersensitivity reactions to spirulina up to anaphylaxis 133135.
| Study | Reported side effects |
|---|---|
| 3 Bayo et al. 2025 | some side effects reported for resveratrol, none stated for Spirulina |
| 5 Rahnama et al. 2023 | not reported in abstract |
| 9 Shahraki et al. 2025 | not reported in abstract |
| 15 Shiri et al. 2025 | not reported in abstract |
| 20 Shu et al. 2025 | Reporting of adverse reactions is called for |
| 21 Lacurezeanu et al. 2025 | no significant adverse effects or organ toxicity reported |
| 31 Reis et al. 2024 | Secondary outcome: adverse drug reactions; no differences reported |
| 35 Saghafi et al. 2025 | safety was a secondary objective, no data reported in abstract |
| 36 Aghasadeghi et al. 2024 | No side effects related to Spirulina supplements observed |
| 37 Barennes et al. 2022 | Tolerance was good |
| 40 Yamani et al. 2009 | Higher creatinemia in spirulina group; possible renal problems mentioned |
| 42 Karimi et al. 2025 | none reported |
6. What Remains Open: Limits of the Evidence
- Many studies are small and of short duration, which limits the transferability of the results.
- The optimal amount and form of preparation is open; the studies used different forms and amounts.
- The difference between Arthrospira platensis and Arthrospira maxima is hardly studied.
- Many studies provide no information on manufacturer funding, which leaves the risk of conflicts of interest open.
- Whether the findings can be transferred to healthy people without metabolic disorders is largely unclear.
7. Bottom Line: What Is Established About Spirulina
Spirulina is the dried biomass of filamentous cyanobacteria of the genus Arthrospira, predominantly Arthrospira platensis and Arthrospira maxima, and is used as a dietary supplement or fortified food. For blood glucose and oxidative stress, controlled trials predominantly show improvements; for body weight, blood lipids and physical performance, meta-analyses are mostly favorable, while the individual studies are inconsistent.
For allergic rhinitis, the evidence is moderate, and the study situation there is less clear. For blood pressure and other endpoints, there are both positive and negative findings. Many studies are small, short and do not always distinguish between the species or forms. The optimal amount, long-term effects and the influence of combination products remain open.
Frequently Asked Questions
How well has Spirulina been studied in humans?
We evaluated 156 human studies on Spirulina, including 76 randomised controlled trials and 29 meta-analyses or systematic reviews; the controlled studies include 6,760 participants in total. As of 8 October 2026.
Does Spirulina help with body weight and body composition? What the studies show
Does Spirulina help with blood lipids? What the studies show
Does Spirulina help with blood glucose and metabolism? What the studies show
Does Spirulina help with oxidative stress and antioxidants? What the studies show
Does Spirulina help with physical performance? What the studies show
Does Spirulina help with blood pressure? What the studies show
What exactly is spirulina?
Spirulina is the dried biomass of filamentous cyanobacteria of the genus Arthrospira, especially Arthrospira platensis and Arthrospira maxima. It is cultivated in open ponds or closed systems and traditionally eaten as dried cakes. Today it serves predominantly as a dietary supplement or protein-rich ingredient in foods. Chlorella, other microalgae and isolated phycocyanin are not the same and are not considered on this page.
Which forms of spirulina were studied in the studies?
The studies predominantly used dried powder of the whole biomass, tablets and capsules as well as foods and drinks enriched with spirulina. Mainly Arthrospira platensis and Arthrospira maxima were studied. Individual studies tested mixtures with chlorella, other algae, turmeric or together with training, so the contribution of spirulina cannot be attributed on its own there. The table shows the amounts tested.
Do the human studies show a benefit?
For blood glucose and oxidative stress, several controlled trials and meta-analyses show improvements; for body weight, blood lipids and physical performance, the individual studies are inconsistent. For blood pressure, there are both positive and negative findings. For allergic rhinitis, the evidence is moderate. Individual studies found no difference, for example in weight or body fat percentage. The results apply in each case to the form and preparation studied.
How well is spirulina tolerated?
Tolerability is predominantly described as good in the studies; in some cases no side effects were observed. Individual studies reported a slight increase in creatinine and occasionally local side effects. Rare hypersensitivity reactions to spirulina up to anaphylaxis have been described. The table shows details.
What should be considered with spirulina products?
Many studies provided no information on manufacturer funding, and information on the purity or composition of a product is not a study result. The optimal amount and form of preparation is open, as are long-term effects. With mixed preparations containing other microalgae or additives, a result cannot be attributed to spirulina alone.
Sources
- 1Osadnik T, Goławski M, Lewandowski P, Morze J, Osadnik K, Pawlas N et al. · 2022
- 2Spirulina supplementation and its effects on inflammation and oxidative stress: A systematic review and Meta-analysis on randomized clinical trialsMousavi S, Yegdaneh A, Shirani M, Feizi A, Ghanadian M · 2025
- 3Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L et al. · 2025
- 4Sukmawati I, Ariyanto H, Heryani H, Sundari SW, Falah M, Rhousnaka D et al. · 2025
- 5Rahnama I, Arabi SM, Chambari M, Bahrami LS, Hadi V, Mirghazanfari SM et al. · 2023
- 6
- 7Wei Y, Liu S, You T, Liu X, Zhong W, Wu Y et al. · 2026
- 8Pinto-Leite M, Martins D, Ferreira AC, Silva C, Trindade F, Saraiva F et al. · 2025
- 9Shahraki Jazinaki M, Rashidmayvan M, Rahbarinejad P, Shadmand Foumani Moghadam MR, Pahlavani N · 2025
- 10Machowiec P, Ręka G, Maksymowicz M, Piecewicz-Szczęsna H, Smoleń A · 2021
- 11Batista IG, Person OC, Bogar P, Angélico Júnior FV · 2021
- 12Azizi Ammarati AH, Shanazari Z, Rahmati M · 2026
- 13Yasul Y, Akbulut T, Çınar V, Yasul ME, Migliaccio GM, Lee DY · 2026
- 14Mishra BK, Kshatri JS, Kulkarni B, Pati S, Dhusiya H, Sethy P et al. · 2026
- 15Shiri H, Yasbolaghi Sharahi J, Alizadeh Sani M, Mousavi SMJ, Nematollahi MH, Soleimani AA et al. · 2025
- 16Kazeminejad S, Arzhang P, Baniasadi MM, Hatami A, Azadbakht L · 2025
- 17Gorgi K, Ghanbarzadegan Z, Darkhosh A, Shojaei-Zarghani S, Hosseini SV · 2025
- 18Shiri H, Soleimani AA, Omidi Sarajar B, Talebi Taheri A, Esmaeili F, Nematollahi MH et al. · 2025
- 19Lak M, Karimi M, Akhgarjand C, Ghotboddin Mohammadi S, Pam P, Ashtary-Larky D et al. · 2025
- 20Shu MY, Liang J, Jo YJ, Eom SH, Kim CH · 2025
- 21Lacurezeanu A, Vodnar DC · 2025
- 22
- 23Fu Y, Du X, Cui Y, Xiong K, Wang J · 2023
- 24Calella P, Di Dio M, Cerullo G, Di Onofrio V, Gallé F, Liguori G · 2022
- 25Calella P, Cerullo G, Di Dio M, Liguori F, Di Onofrio V, Gallè F et al. · 2022
- 26Hatami E, Ghalishourani SS, Najafgholizadeh A, Pourmasoumi M, Hadi A, Clark CCT et al. · 2021
- 27Bobescu E, Bălan A, Moga MA, Teodorescu A, Mitrică M, Dima L · 2020
- 28Huang H, Liao D, Pu R, Cui Y · 2018
- 29Laccourreye O, Werner A, Laccourreye L, Bonfils P · 2017
- 30Karkos PD, Leong SC, Arya AK, Papouliakos SM, Apostolidou MT, Issing WJ · 2007
- 31Reis G, Augusto Dos Santos Moreira Silva E, Carla Medeiros Silva D, Thabane L, Santiago Ferreira T, Vitor Quirino Dos Santos C et al. · 2024
- 32
- 33
- 34Othoo DA, Ochola S, Kuria E, Kimiywe J · 2021
- 35Saghafi F, Zare P, Hatamizadeh N, Malmir M, Sahebnasagh A · 2025
- 36Aghasadeghi MR, Zaheri Birgani MA, Jamalimoghadamsiyahkali S, Hosamirudsari H, Moradi A, Jafari-Sabet M et al. · 2024
- 37Barennes H, Houdart L, de Courville C, Barennes F · 2022
- 38Ngo-Matip ME, Pieme CA, Azabji-Kenfack M, Moukette BM, Korosky E, Stefanini P et al. · 2015
- 39Ngo-Matip ME, Pieme CA, Azabji-Kenfack M, Biapa PC, Germaine N, Heike E et al. · 2014
- 40[Use of spirulina supplement for nutritional management of HIV-infected patients: study in Bangui, Central African Republic]Yamani E, Kaba-Mebri J, Mouala C, Gresenguet G, Rey JL · 2009
- 41Hatami M, Mojani-Qomi MS, Javid Z, Taghavi M, Bakhshandeh H, Sanaei Delir Zavaragh D et al. · 2023
- 42Karimi S, Shaygannejad V, Mohammadalipour A, Feizi A, Hooshmand S, Kafeshani M · 2025
- 43Moradi S, Bagheri R, Amirian P, Zarpoosh M, Cheraghloo N, Wong A et al. · 2024
- 44Moradi S, Foshati S, Poorbaferani F, Talebi S, Bagheri R, Amirian P et al. · 2023
- 45Choi WY, Lee WK, Kim TH, Ryu YK, Park A, Lee YJ et al. · 2022
- 46Moradi S, Zobeiri M, Feizi A, Clark CCT, Entezari MH · 2021
- 47
- 48Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY · 2008
- 49Winter FS, Emakam F, Kfutwah A, Hermann J, Azabji-Kenfack M, Krawinkel MB · 2014
- 50Phansuea P, Chotchindakun K, Sahasakul Y, Phattaramarut K, Kuntanawat P · 2025
- 51
- 52Papakonstantinou E, Lympaki F, Savvidou A, Dalaka E, Georgiopoulos G, Giannoglou M et al. · 2026
- 53Delfan M, Negin Zeidi HA, Kashani FR, Zeynali F, Juybari RA, Rahimpour M et al. · 2026
- 54Hossein N, Mehdi M, Karim D, Mahdi M, Ghasemi E · 2025
- 55Nasab SJ, Feizi A, Hajihashemi P, Entezari MH, Sharma M, Adibi P et al. · 2025
- 56Tamtaji OR, Heidari-Soureshjani R, Asemi Z, Kouchaki E · 2023
- 57Karizi SR, Armanmehr F, Azadi HG, Zahroodi HS, Ghalibaf AM, Bazzaz BSF et al. · 2023
- 58Chaitanya NC, Chikte D, Kumar YP, Komali G, Yellarthi SP, Reddy CS et al. · 2022
- 59Mohammad M, Karim D, Mehdi M, Marziyeh S, Hadi S, Shila N · 2022
- 60Hernández-Lepe MA, Wall-Medrano A, López-Díaz JA, Juárez-Oropeza MA, Hernández-Torres RP, Ramos-Jiménez A · 2019
- 61Hernández-Lepe MA, Olivas-Aguirre FJ, Gómez-Miranda LM, Hernández-Torres RP, Manríquez-Torres JJ, Ramos-Jiménez A · 2019
- 62
- 63Asadolah-Poor-Kashi MZ, Mamsharifi P, Haerifar F, Simani M, Ghaderi A, Mehrzad F · 2026
- 64Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: a randomized double-blind placebo-controlled studySzulinska M, Gibas-Dorna M, Miller-Kasprzak E, Suliburska J, Miczke A, Walczak-Gałezewska M et al. · 2017
- 65Suliburska J, Szulińska M, Tinkov AA, Bogdański P · 2016
- 66Ghaem Far E, Babajafari S, Ghaem Far Z, Mohammadi S, Nouri M, Kojuri J et al. · 2025
- 67Ghaem Far Z, Babajafari S, Kojuri J, Mohammadi S, Nouri M, Rostamizadeh P et al. · 2021
- 68Mazloomi SM, Samadi M, Davarpanah H, Babajafari S, Clark CCT, Ghaemfar Z et al. · 2022
- 69Delfan M, Saeidi A, Supriya R, Escobar KA, Laher I, Heinrich KM et al. · 2024
- 70Supriya R, Delfan M, Saeidi A, Samaie SS, Al Kiyumi MH, Escobar KA et al. · 2023
- 71Spirulina Platensis Attenuates Rebound Dyspeptic Symptoms After Proton Pump Inhibitors' Discontinuation: Phase 2 Placebo-controlled TrialGronevalt ATM, Bertolin TE, Forcelini CM, Polletto PHM, Pasetti BW, Graeff DB et al. · 2024
- 72Gómez-Téllez A, Sierra-Puente D, Muñoz-Gómez R, Ibarra-Pitts A, Guevara-Cruz M, Hernández-Ortega M et al. · 2020
- 73Misbahuddin M, Islam AZ, Khandker S, Ifthaker-Al-Mahmud, Islam N, Anjumanara · 2006
- 74Pour AS, Hemmatinafar M, Jahromi MK, Daryanoosh F, Imanian B · 2026
- 75Rezaiyan M, Sasani N, Kazemi A, Mohsenpour MA, Babajafari S, Mazloomi SM et al. · 2023
- 76Koite NLN, Sanogo NI, Lépine O, Bard JM, Ouguerram K · 2022
- 77Bagheri R, Negaresh R, Motevalli MS, Wong A, Ashtary-Larky D, Kargarfard M et al. · 2022
- 78Modarresi R, Aminsharifi A, Foroughinia F · 2019
- 79Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind, placebo-controlled, randomized trialMiczke A, Szulińska M, Hansdorfer-Korzon R, Kręgielska-Narożna M, Suliburska J, Walkowiak J et al. · 2016
- 80Akbarzadeh Khadari H, Fazolahzade Mousavi R, Hosseini Abrishami L · 2025
- 81van der Heijden I, West S, Monteyne AJ, Finnigan TJA, Abdelrahman DR, Murton AJ et al. · 2023
- 82van den Driessche JJ, Plat J, Konings MCJM, Mensink RP · 2020
- 83Marcel AK, Ekali LG, Eugene S, Arnold OE, Sandrine ED, von der Weid D et al. · 2011
- 84de Almeida PC, da Rosa Lima T, Pereira Avila ET, Brito GA, Malheios NO, Vilela Leal R et al. · 2026
- 85Chowdhar AR, Wadde K, Sachdev SS, Latke S, Kumar B · 2025
- 86Leal-Martínez F, Franco D, Peña-Ruiz A, Castro-Silva F, Escudero-Espinosa AA, Rolón-Lacarrier OG et al. · 2020
- 87Chronic viral hepatitis, the treatment with spiruline for one month has no effect on the aminotransferasesBăicuş C, Tănăsescu C · 2002
- 88Dolly AS, Shankar PLR, Saravanan AV, Pandian KR, Sindhujaa R, Rashik KMM · 2024
- 89van der Heijden I, West S, Monteyne AJ, Finnigan TJA, Abdelrahman DR, Murton AJ et al. · 2024
- 90Chaouachi M, Gautier S, Carnot Y, Bideau N, Guillemot P, Moison Y et al. · 2021
- 91Gurney T, Brouner J, Spendiff O · 2025
- 92Golestani F, Mogharnasi M, Erfani-Far M, Abtahi-Eivari SH · 2021
- 93Juszkiewicz A, Basta P, Petriczko E, Machaliński B, Trzeciak J, Łuczkowska K et al. · 2018
- 94
- 95Chaouachi M, Gautier S, Carnot Y, Guillemot P, Pincemail J, Moison Y et al. · 2022
- 96Martínez-Sámano J, Torres-Montes de Oca A, Luqueño-Bocardo OI, Torres-Durán PV, Juárez-Oropeza MA · 2018
- 97Lympaki F, Giannoglou M, Magriplis E, Bothou DL, Andreou V, Dimitriadis GD et al. · 2022
- 98Gurney T, Spendiff O · 2020
- 99Williamson E, Monteyne AJ, Van der Heijden I, Abdelrahman DR, Murton AJ, Hankamer B et al. · 2024
- 100Baicus C, Baicus A · 2007
- 101Rada Markova, Iren Tzotcheva, Penka Perenovska, Atanas Mangarov, Lubomira Nikolaeva–Glomb, Veselin Hadjiev · Folia Medica · 2023
- 102Javid Z, Santos HO, Norouzi M, Taghavi M, Hatami M, Nazari M et al. · 2023
- 103Hernández-Lepe MA, López-Díaz JA, Juárez-Oropeza MA, Hernández-Torres RP, Wall-Medrano A, Ramos-Jiménez A · 2018
- 104Hernández-Lepe MA, López-Díaz JA, Juárez-Oropeza MA, Hernández-Torres RP, Wall-Medrano A, Ramos-Jiménez A · 2018
- 105Johnson M, Hassinger L, Davis J, Devor ST, DiSilvestro RA · 2016
- 106
- 107Mahendra J, Mahendra L, Muthu J, John L, Romanos GE · 2013
- 108Kaipa VRK, Asif SM, Assiri KI, Saquib SA, Arem SA, Sree S et al. · 2022
- 109Ismail M, Hossain MF, Tanu AR, Shekhar HU, Shekhar HU · 2015
- 110Tayebi SM, Bagherian P, Bassami M, Basereh A, Ahmadabadi S · 2025
- 111Stancioiu F, Mihai D, Papadakis GZ, Tsatsakis A, Spandidos DA, Badiu C · 2019
- 112Samuels R, Mani UV, Iyer UM, Nayak US · 2002
- 113Reich K, Trettel N, Reich JLK, Sorbe C, Bickert T, Hartmann J et al. · 2025
- 114van der Wielen N, Khodorova NV, Gerrits WJJ, Gaudichon C, Calvez J, Tomé D et al. · 2020
- 115Kalafati M, Jamurtas AZ, Nikolaidis MG, Paschalis V, Theodorou AA, Sakellariou GK et al. · 2010
- 116Krokidas A, Gakis AG, Aktypi O, Antonopoulou S, Nomikos T · 2024
- 117Ghafari Ashtiani A, Sharifan A, Gharibi M, Moradzadeh R · 2024
- 118Cingi C, Conk-Dalay M, Cakli H, Bal C · 2008
- 119Mathew B, Sankaranarayanan R, Nair PP, Varghese C, Somanathan T, Amma BP et al. · 1995
- 120Kashyap GC, Sarala R, Manjunath U · 2022
- 121Karrento K, Chumpitazi BP, Zhang L, Simpson P, Shulman RJ · 2026
- 122Sayin I, Cingi C, Oghan F, Baykal B, Ulusoy S · 2013
- 123[Selenium deficiency and its dietary correction in patients with irritable bowel syndrome and chronic catarrhal colitis]Bogatov NV · 2007
- 124Viramontes BE, Kim DY, Camilleri M, Lee JS, Stephens D, Burton DD et al. · 2001
- 125Alshafei MM, Ziada YM, Saber MM, Dawood EM, Mabrouk AM, El-Messery TM et al. · 2025
- 126Selmi C, Leung PS, Fischer L, German B, Yang CY, Kenny TP et al. · 2011
- 127Bharucha AE, Kudva Y, Basu A, Camilleri M, Low PA, Vella A et al. · 2015
- 128Devi S, Varkey A, Sheshshayee MS, Preston T, Kurpad AV · 2018
- 129Ferreira-Hermosillo A, Torres-Duran PV, Juarez-Oropeza MA · 2010
- 130Vankawala J, Altweiss E, Glaeser AM · 2025
- 131Yadav P, Stigall K, Johnson HE, Rayapati AO, Chopra N · 2016
- 132Jester BW, Zhao H, Gewe M, Adame T, Perruzza L, Bolick DT et al. · 2022
- 133Gromek W, Kołdej N, Kurowski M, Majsiak E · 2024
- 134
- 135Srisuwatchari W, Norchai P · 2026
- 136Ibrahim MEE, Demirel S, Yıkmış S, Tokatlı Demirok N, Ahmed MBO, Amin AK · 2026
- 137
- 138Wang Z, Scherbinek M, Skurk T · 2026
- 139Diniz AFA, Barros BC, da Silva JMA, Arruda RRA, Claudino BFO, de Melo MB et al. · 2025
- 140Alves JLB, Costa PCTD, Sales LCS, Silva Luis CC, Bezerra TPT, Souza MLA et al. · 2025
- 141Tranchida N, Molinari F, Franco GA, Cordaro M, Di Paola R · 2025
- 142Janota B, Janion K, Buzek A, Janczewska E · 2025
- 143
- 144Prete V, Abate AC, Di Pietro P, De Lucia M, Vecchione C, Carrizzo A · 2024
- 145Służały P, Paśko P, Galanty A · 2024
- 146Chaouachi M, Vincent S, Groussard C · 2024
- 147Mishra A, Krishnamurthy S · 2024
- 148Januszewski J, Forma A, Zembala J, Flieger M, Tyczyńska M, Dring JC et al. · 2023
- 149Sibiya T, Ghazi T, Chuturgoon A · 2022
- 150Sorrenti V, Castagna DA, Fortinguerra S, Buriani A, Scapagnini G, Willcox DC · 2021
- 151Ramos-Romero S, Torrella JR, Pagès T, Viscor G, Torres JL · 2021
- 152Finamore A, Palmery M, Bensehaila S, Peluso I · 2017
- 153Braakhuis AJ, Hopkins WG · 2015
- 154Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA · 2011
- 155Deng R, Chow TJ · 2010
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.